Share

July 2020; 7 (4) ArticleOpen Access

Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder

Andrea Ines Ciplea, Annette Langer-Gould, Annick de Vries, Tiny Schaap, Sandra Thiel, Marius Ringelstein, Ralf Gold, Kerstin Hellwig
First published April 23, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000723
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1818

Share

Article Figures & Data

Figures

  • Figure
    Figure Natalizumab concentration in breast milk and blood samples of mothers and their breastfed infants

    Left: natalizumab concentrations (in micrograms per milliliter) in the breast milk of mothers 2 and 3 on several days after the first infusion postpartum and of mother 1 on several days after the fourth infusion postpartum. Right: natalizumab concentration (in micrograms per milliliter) in sera of mothers 2 and 3 and babies 2 and 3. Maternal serum concentrations were measured at 2 time points after the first infusion postpartum; the serum level of baby 2 was measured before and at 2 points after the first infusion postpartum; for baby 3, it was available only at 1 time point after the first infusion. aBelow the detection limit; bSample stability issues.

Tables

  • Table 1
  • Table 2
  • Table 3
  • Table 4
  • Table5

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles